



June 12, 2013

**BY EMAIL**

Ms. Mary Catherine Lindberg, Chairperson  
Patented Medicine Prices Review Board (PMPRB)

A/S Sylvie Dupont  
Director, Board Secretariat and Communication, PMPRB  
Box L40, Standard Life Centre  
333 Laurier Avenue West, Suite 1400  
Ottawa, Ontario K1P 1C1  
[sylvie.dupont@pmprb-cepmb.gc.ca](mailto:sylvie.dupont@pmprb-cepmb.gc.ca)

**SUBJECT: PMPRB Proposed Changes to the CPI Adjustment Methodology and Filing Requirements**

Dear Ms. Lindberg,

Sanofi-aventis Canada Inc. would like to confirm its support to the Board proposal which is to initiate a consultation addressing the following proposed changes.

1. Consumer Price Index (CPI) Adjustment Methodology  
*PMPRB Proposal for Consideration: "Maintain current CPI Adjustment Methodology for existing drug products, except replace the use of the forecast CPI with actual CPI in calculating the CPI Adjustment Factor for the forecast period."*
2. Reduction of Filing Requirements – Yearly Reporting  
*PMPRB Proposal for Existing Patented Drugs: "For existing drug products, to replace the semi-annual regulatory filing of Form 2- Information on the identity and prices of the medicine by an annual filing."*
3. Reduction of Filing Requirements – Form Changes  
*PMPRB Proposal for New Patented Drugs: "To eliminate the requirement to submit Form 2 information for the first day of sales of a patented drug product in Canada and to add a section in the Form 1-Medicine Identification Sheet to report the publicly available ex-factory price in Canada on the date of first sale."*

We hope that the official consultation process will start promptly and we are looking forward to providing you with further detailed comments on each if these changes.

Sincerely,

A handwritten signature in black ink, appearing to read "Jacinte Morel".

Jacinte Morel  
Senior Manager, Pricing Strategies

CC. Pat Papillo, Vice-President Finance